BioNTech will wind up its vaccine manufacturing plant in Singapore by February 2027 after a strategic review. Read more at straitstimes.com. Read more at straitstimes.com.
The Phase II cohort analysis included 145 patients whose conditions had progressed following initial chemotherapy.
BioNTech has a rich pipeline that could help jolt the stock as it makes clinical progress. Intellia Therapeutics faces ...
Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of ...
The German biotechnology company currently employs 85 people at its manufacturing plant in Tuas.
Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall ...
The fight for two tumor types is poised to intensify, with BioNTech lining up a challenge to AstraZeneca, while SynOx Therapeutics is planning to enter a market served by companie ...
Amid growing financial concerns and US vaccine hesitancy, the German company will close its mRNA site in Southeast Asia.
The company's shares recently gained nearly 10% in a week, closing at 87.00 EUR, as it presented compelling evidence for its strategic shift into oncology. The most striking data came from a Phase 2 ...
Trastuzumab pamirtecan, a HER2-targeted antibody-drug conjugate, achieved ‘exceptional’ antitumor responses in patients with recurrent endometrial cancer, especially those with HER2 IHC 3+ tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results